CMRX Chimerix Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CMRX

Price (delayed)

$0.8925

Market cap

$79.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.94

Enterprise value

$61.97M

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious ...

Highlights
The debt has contracted by 40% YoY and by 23% from the previous quarter
The net income has plunged by 147% YoY
The EPS has plunged by 147% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.chimerix.com
Peers: EBS MRK GILD SIGA

Key stats

What are the main financial stats of CMRX
Market
Shares outstanding
89.63M
Market cap
$79.99M
Enterprise value
$61.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.46
Price to sales (P/S)
1,943.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,511.55
Earnings
Revenue
$41,000
EBIT
-$82.59M
EBITDA
-$82.6M
Free cash flow
-$64.43M
Per share
EPS
-$0.94
Free cash flow per share
-$0.72
Book value per share
$1.95
Revenue per share
$0
TBVPS
$2.17
Balance sheet
Total assets
$194.04M
Total liabilities
$19.94M
Debt
$1.01M
Equity
$174.1M
Working capital
$144.1M
Liquidity
Debt to equity
0.01
Current ratio
8.61
Quick ratio
8.4
Net debt/EBITDA
0.22
Margins
EBITDA margin
-201,453.7%
Gross margin
100%
Net margin
-201,443.9%
Operating margin
-227,407.3%
Efficiency
Return on assets
-37.8%
Return on equity
-41.3%
Return on invested capital
-45.3%
Return on capital employed
-47.2%
Return on sales
-201,443.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CMRX stock price

How has the Chimerix stock price performed over time
Intraday
0.28%
1 week
-0.83%
1 month
1.42%
1 year
-23.72%
YTD
-7.27%
QTD
1.42%

Financial performance

How have Chimerix's revenue and profit performed over time
Revenue
$41,000
Gross profit
$41,000
Operating income
-$93.24M
Net income
-$82.59M
Gross margin
100%
Net margin
-201,443.9%
The net income has plunged by 147% YoY
Chimerix's revenue has plunged by 100% YoY and by 87% from the previous quarter
The company's gross profit has shrunk by 100% YoY and by 87% QoQ
The operating income has shrunk by 56% YoY

Growth

What is Chimerix's growth rate over time

Valuation

What is Chimerix stock price valuation
P/E
N/A
P/B
0.46
P/S
1,943.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,511.55
The EPS has plunged by 147% YoY
The stock's price to book (P/B) is 84% less than its 5-year quarterly average of 2.9 and 10% less than its last 4 quarters average of 0.5
The equity has declined by 28% year-on-year and by 10% since the previous quarter
CMRX's P/S is 191% higher than its last 4 quarters average of 662.3
Chimerix's revenue has plunged by 100% YoY and by 87% from the previous quarter

Efficiency

How efficient is Chimerix business performance
CMRX's return on assets has dropped by 148% year-on-year and by 8% since the previous quarter
Chimerix's return on equity has shrunk by 147% YoY and by 9% QoQ
Chimerix's ROIC has plunged by 130% YoY and by 10% from the previous quarter

Dividends

What is CMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMRX.

Financial health

How did Chimerix financials performed over time
The current ratio has declined by 37% year-on-year and by 16% since the previous quarter
CMRX's quick ratio is down by 36% year-on-year and by 15% since the previous quarter
The debt is 99% less than the equity
The debt has contracted by 40% YoY and by 23% from the previous quarter
The equity has declined by 28% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.